Premier Path Wealth Partners LLC Sells 467 Shares of Edwards Lifesciences Co. (NYSE:EW)

Premier Path Wealth Partners LLC reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 3,807 shares of the medical research company’s stock after selling 467 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Edwards Lifesciences were worth $282,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC increased its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $40,000. Finally, Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $46,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 0.1 %

Shares of NYSE EW opened at $69.77 on Monday. The stock has a market capitalization of $41.15 billion, a P/E ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a fifty day moving average price of $72.06 and a 200 day moving average price of $71.32. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 EPS. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities research analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on EW. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a report on Thursday, December 5th. The Goldman Sachs Group increased their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a report on Thursday. Finally, Piper Sandler reduced their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $78.48.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,000 shares of company stock valued at $2,195,180. Corporate insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.